Browse News
Filter News
Found 25 articles
-
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and...
4/18/2024
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, recently completed two Phase 3 trials, OA-07 long-term structure, pain and function study, and OA-21 short-term pain study.
-
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
3/8/2024
Biosplice Therapeutics, Inc. announced that its collaboration with The Roskamp Institute, aimed at developing novel therapies for TBI using Biosplice’s promising small molecule DYRK inhibitors has been selected for funding by the DoD office of the Congressionally Directed Medical Research Programs.
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
2/8/2024
Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet's Disease.
-
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
11/13/2023
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, yesterday presented results from a long-term extension study, OA-07 for its knee OA drug candidate, lorecivivint.
-
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
3/2/2023
Lantern Pharma Inc. today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members.
-
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
12/15/2022
Biosplice Therapeutics, Inc. announced potential structure-modifying highlights from an ongoing long-term extension study, OA-07, for its knee OA drug candidate, lorecivivint.
-
IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
11/28/2022
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Darrin M. Beaupre, M.D., Ph.D., has joined the company as its Chief Medical Officer, effective November 21, 2022.
-
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
11/11/2022
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced highlights from three Phase 3 clinical trials, OA-07, OA-10 and OA-11 for its knee OA drug candidate, lorecivivint.
-
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting
9/29/2022
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced today the presentation of new clinical data for cirtuvivint (SM08502), its first-in-class small-molecule CLK/DYRK inhibitor.
-
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
5/11/2022
Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies for metabolic and chronic conditions, today reported the completion of a Phase 1 trial for its lead clinical-stage program, GLY-200, as a treatment for type 2 diabetes (T2D).
-
Biocept Appoints Philippe Marchand as Chief Operating Officer
3/8/2022
Biocept, Inc has appointed Philippe Marchand, Ph.D., to the position of Chief Operating Officer, effective today.
-
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
2/22/2022
Veracyte, Inc. today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately.
-
EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS
1/27/2022
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice's clinical oncology programs, including Cirtuvivint (SM08502).
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in OncologyThis trial will evaluate the clinical safety and efficacy of orally administered cirtuvivint (SM08502) in multiple combination cohorts
11/17/2021
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a Phase 1b, open-label, multi-center, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.
-
Sonendo Appoints Three New Members to Board of Directors
11/3/2021
Sonendo, Inc. today announced the appointment of three new members to its Board of Directors.
-
Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
9/15/2021
Biosplice Therapeutics, Inc. (“Biosplice”), and Haisco Pharmaceutical Group Co., Ltd. (“Haisco”), a pharmaceutical company based in the People’s Republic of China (“China”), announced the execution of a licensing agreement that grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal conditions in China.
-
Clinical Catch-Up: July 19-23
7/26/2021
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more. -
Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
7/22/2021
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of a post-hoc analysis of its successful Phase 2b knee osteoarthritis clinical trial in Rheumatology and Therapy.
-
Dave Johnson Joins Biosplice Therapeutics Board of Directors
6/21/2021
Biosplice Therapeutics, Inc. announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.